Yes agreed. I'm not too fussed if they're in the bottom end of guidance because it's still early in development and the reality is no one is going to put in a buy offer for Neuren based on acquiring 10-15% of Daybue. Takeover offers that can drive the SP up will be predominantly about 2591. It's just frustrating that the market currently hasn't made that shift. With the recent lack of reaction to the PH results I'm not sure what a positive Angelman readout would do but personally I have faith that a follow up drug that's related in mechanism to an effective approved drug and has three promising Phase 2s will be getting a lot of attention.
Acadia, page-622
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.17 |
Change
1.180(5.62%) |
Mkt cap ! $2.805B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.44 | $21.50 | $11.46M | 522.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 5657 | $23.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.07 | 1602 | 2 |
View Market Depth
| Last trade - 15.59pm 17/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |